We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

170 hedge funds and large institutions have $2.3B invested in Intra-Cellular Therapies Inc. in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 66 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $18.3M

8% more capital invested

Capital invested by funds: $2.13B → $2.3B (+$168M)

4% less funds holding

Funds holding: 178 → 170 (-8)

21% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 29

24% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 66

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
170
Holders Change
-8
Holders Change %
-4.49%
% of All Funds
2.99%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
23
Increased
50
Reduced
66
Closed
29
Calls
$22.7M
Puts
$18.3M
Net Calls
+$4.39M
Net Calls Change
-$4.39M

Top Buyers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$73.6M
2
Franklin Resources
Franklin Resources
California
+$40.5M
3
TCM
TimesSquare Capital Management
New York
+$11.7M
4
Invesco
Invesco
Georgia
+$9.74M
5
BlackRock
BlackRock
New York
+$9M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$27.6M
2
MWNA
Marshall Wace North America
New York
-$15.3M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$13.7M
4
SC
Samlyn Capital
New York
-$10.1M
5
Norges Bank
Norges Bank
Norway
-$8.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
MS
176
Maven Securities
Jersey
– -$591K -18,342 Closed
OMC
177
Old Mission Capital
Illinois
– -$463K -14,570 Closed
E
178
Ergoteles
New York
– -$461K -14,500 Closed
Rafferty Asset Management
179
Rafferty Asset Management
New York
– -$371K -11,666 Closed
WAM
180
Wolverine Asset Management
Illinois
– -$356K -11,222 Closed
Natixis Advisors
181
Natixis Advisors
Massachusetts
– -$342K -10,758 Closed
Squarepoint
182
Squarepoint
New York
– -$341K -10,728 Closed
PCH
183
Polar Capital Holdings
United Kingdom
– -$336K -10,558 Closed
HF
184
HRT Financial
New York
– -$335K -10,545 Closed
YIH
185
Y-Intercept (HK)
Hong Kong
– -$337K -10,453 Closed
Walleye Trading
186
Walleye Trading
New York
– -$356K -10,258 Closed
MML Investors Services
187
MML Investors Services
Massachusetts
– -$304K -9,570 Closed
Los Angeles Capital Management
188
Los Angeles Capital Management
California
– -$290K -9,132 Closed
HSBC Holdings
189
HSBC Holdings
United Kingdom
– -$290K -9,088 Closed
ACM
190
AlphaCrest Capital Management
New York
– -$264K -8,300 Closed
MSL
191
Mackay Shields LLC
New York
– -$261K -8,200 Closed
JCM
192
JS Capital Management
New York
– -$232K -7,300 Closed
VRS
193
Virginia Retirement Systems
Virginia
– -$216K -6,800 Closed
NICM
194
Neo Ivy Capital Management
New York
– -$111K -3,495 Closed
ASN
195
Advisory Services Network
Georgia
– -$25K -775 Closed
HI
196
Harbour Investments
Wisconsin
– +$35 +1 New
BCA
197
Berman Capital Advisors
Georgia
– +$208 +6 New
4 5 6 7
8

ITCI Hedge Fund Activity: Q1 2021 in Review

170 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2021, worth a combined $2.3B — up 7.9% from $2.13B a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ITCI and 23 opened new positions — a net loss of 6 holders — while 66 trimmed existing stakes and 50 added.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $73.6M. The largest seller was Millennium Management, cutting an estimated $27.6M.

  • 170 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2021, down from 178 in Q4 2020.
  • Funds reported $2.3B of Intra-Cellular Therapies Inc. stock for Q1 2021, up 7.9% quarter-over-quarter.
  • 23 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2021 and 29 closed out, a net change of -6 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2021 was Lord, Abbett & Co, an estimated $73.6M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2021 was Millennium Management, an estimated $27.6M sold.

Based on aggregated 13F filings for Q1 2021.